Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.…
Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London
Turn Therapeutics (NASDAQ: TTRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 8.095 USD on 20 November 2026, up 186.0% over 52 weeks. Its 52-week range is 2.570 USD to 16.45 USD: the price is 50.8% below the high and 215.0% above the low.
Its market capitalisation is 247.49M USD.
Turn Therapeutics reports return on equity of -68.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 4.13M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 25.00 USD is 208.8% above the current price. The next earnings report is expected on 31 March 2027.